• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Benign Prostatic Hyperplasia - Pipeline Review, H1 2012 Product Image

Benign Prostatic Hyperplasia - Pipeline Review, H1 2012

  • Published: February 2012
  • 111 pages
  • Global Markets Direct

Benign Prostatic Hyperplasia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Benign Prostatic Hyperplasia - Pipeline Review, H1 2012', provides an overview of the Benign Prostatic Hyperplasia therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia. 'Benign Prostatic Hyperplasia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Benign Prostatic Hyperplasia.
- A review of the Benign Prostatic READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Benign Prostatic Hyperplasia Overview
Therapeutics Development
An Overview of Pipeline Products for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia Therapeutics under Development by Companies
Benign Prostatic Hyperplasia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Benign Prostatic Hyperplasia Therapeutics – Products under Development by Companies
Benign Prostatic Hyperplasia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Benign Prostatic Hyperplasia Therapeutics Development
Allergan, Inc.
Eli Lilly and Company
Euroscreen S.A.
Light Sciences Oncology, Inc.
Aphios Corporation
Astellas Pharma Inc.
Dong-A Pharmaceutical Co., Ltd.
Kissei Pharmaceutical Co., Ltd.
Bayer AG
Addex Pharmaceuticals
AEterna Zentaris Inc.
Nymox Pharmaceutical Corporation
Plethora Solutions Holdings plc
Protox Therapeutics Inc.
Ajanta Pharma Limited
AndroScience Corporation
Vantia Therapeutics
World of Health Biotech Co.Ltd
Pherin Pharmaceuticals, Inc.
Ausio Pharmaceuticals, LLC
Benign Prostatic Hyperplasia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Cetrotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEZS-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX68692 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sperol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NX-1207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASC-JM.X2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PSD506 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VA106483 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aptocine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aptocine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRX302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pomegranate Tablets - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zydena - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tamsulosin Hydrochloride + Solifenacin Succinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tadalafil + Finasteride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Silodosin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-O-M MCS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levitra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BoNT/A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PH45 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BOTOX-A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
botulinum toxin type A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TUC202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naftopidil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tamsulosin + Meloxicam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botulinum toxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP4901 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY500307 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KSO-0400 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP0306 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Benign Prostatic Hyperplasia Therapeutics – Drug Profile Updates
Benign Prostatic Hyperplasia Therapeutics – Discontinued Products
Benign Prostatic Hyperplasia Therapeutics - Dormant Products
Benign Prostatic Hyperplasia – Product Development Milestones
Featured News & Press Releases
Dec 22, 2011: Protox Completes Dosing Of Second Cohort Of Patients In Transrectal Study
Nov 22, 2011: Nymox Provides Safety Monitoring Committee Results And Update For Pivotal Phase III NX-1207 Trials
Nov 04, 2011: Nymox Announces Presentation On NX-1207 Prostate Drug At American Urological Association Meeting
Oct 31, 2011: Nymox Presents Long Term Results On NX-1207 BPH Drug At American Urological Association Meeting In New Orleans
Oct 20, 2011: Protox Completes Dosing Of First Cohort Of Patients In Transrectal Study
Oct 19, 2011: Nymox Presents New Positive Data On NX-1207 At American Urological Association Meeting
Oct 12, 2011: New Study Shows Cialis Significantly Improved Study Endpoints In Men With Both Erectile Dysfunction And Signs And Symptoms Of Benign Prostatic Hyperplasia
Oct 11, 2011: Nymox To Present New Clinical Trial Data Of NX-1207 At Orlando Meeting Of American Urological Association
Oct 07, 2011: Lilly Receives FDA Approval For Cialis To Treat Men With Signs And Symptoms Of Benign Prostatic Hyperplasia And Men With Both Erectile Dysfunction And Signs And Symptoms Of BPH
Oct 04, 2011: Nymox Announces Presentation Of Results On NX-1207 BPH Drug At American Urological Association Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Benign Prostatic Hyperplasia, H1 2012
Products under Development for Benign Prostatic Hyperplasia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Allergan, Inc., H1 2012
Eli Lilly and Company, H1 2012
Euroscreen S.A., H1 2012
Light Sciences Oncology, Inc., H1 2012
Aphios Corporation, H1 2012
Astellas Pharma Inc., H1 2012
Dong-A Pharmaceutical Co., Ltd., H1 2012
Kissei Pharmaceutical Co., Ltd., H1 2012
Bayer AG, H1 2012
Addex Pharmaceuticals, H1 2012
AEterna Zentaris Inc., H1 2012
Nymox Pharmaceutical Corporation, H1 2012
Plethora Solutions Holdings plc, H1 2012
Protox Therapeutics Inc., H1 2012
Ajanta Pharma Limited, H1 2012
AndroScience Corporation, H1 2012
Vantia Therapeutics, H1 2012
World of Health Biotech Co.Ltd, H1 2012
Pherin Pharmaceuticals, Inc., H1 2012
Ausio Pharmaceuticals, LLC, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Benign Prostatic Hyperplasia Therapeutics – Drug Profile Updates
Benign Prostatic Hyperplasia Therapeutics – Discontinued Products
Benign Prostatic Hyperplasia Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2012
Products under Development for Benign Prostatic Hyperplasia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos